USO 25219

A randomized, open-label, 3-arm Phase 3 study of precemtabart tocentecan with or without bevacizumab compared to trifluridine/tipiracil plus bevacizumab in participants with previously treated metastatic colorectal cancer (PROCEADE-CRC-03)

Disease Types: Gastrointestinal Cancer Research

Eligibility Requirements:

*Participants with documented histopathological diagnosis of metastatic colorectal cancer, who were intolerant to, or whose disease was refractory to, or progressed after standard systemic therapies and no more than 2 previous systemic treatment regimens in the  metastatic setting.
*Participants must have received and progressed on no more than 2 previous systemic treatment regimens in the metastatic setting.
*Eastern Cooperative Oncology Group (ECOG) performance status less than equal to 1.
*Participants must be able to swallow oral tablets, and to comply with the study requirements for all scheduled evaluations.
*Other protocol defined inclusion criteria may apply.

*For more details on this trial CLICK HERE .

Available at:

• Chesapeake
• Hampton (CarePlex)
• Newport News (Port Warwick III)
• Norfolk (Brock Cancer Center)
• Suffolk (Harbour View)
• Virginia Beach (Princess Anne)
• Williamsburg